Join Dr. Agne Straukiene, a neurologist specialising in Multiple Sclerosis, as she unveils groundbreaking treatments discussed at the ECTRIMS 2025 conference. Discover how BTK inhibitors like #Tolebrutinib, #Evobrutinib, #Orelabrutinib, #Remibrutinib, and #Fenebrutinib could revolutionize MS care by targeting both B cells and brain cells to reduce inflammation and progression. Learn about #Frexalimab's novel mechanism and promising trial results, the potential of combining #Clemastine and #Metformin for myelin repair, and remarkable long-term outcomes of autologous haematopoietic stem cell transplantation. Explore the exciting advent of #CART cell therapy poised to change the future of MS treatment.
00:00 Introduction to MS and ECTRIMS 2025 00:24 Understanding BTK Inhibitors 01:05 Key BTK Inhibitors Discussed 04:00 Frexalimab: A New Approach 05:09 Combination Therapies: Clemastine and Metformin 06:05 Stem Cell Therapy: Long-term Outcomes 07:43 CAR T Cell Therapy: Cutting-edge Treatment 08:57 Conclusion and Future Outlook
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr Agne Straukiene. Innehållet i podden är skapat av Dr Agne Straukiene och inte av,
eller tillsammans med, Poddtoppen.
